



# FY2023 Q3 YTD Financial Results



Our dengue vaccine has now launched in  
**21 countries**

including **four endemic** countries.

As of February 1, 2024



# 2 new drug approvals

from the U.S. FDA

And **multiple life-cycle management approvals** since the beginning of Q3



Revenue

¥3,212.9<sub>B</sub>

Flat at CER; +4.6% growth at AER



Core Operating Profit

¥865.6B

-9.3% change at Actual Exchange Rate,  
-12.7% change at Constant Exchange  
Rate (CER) reflects generic impact,  
lower coronavirus vaccines revenue  
and increased investment in R&D and  
data, digital & technology

Core Operating  
Profit Margin

26.9%

Reported Operating  
Profit

¥224.1B

-44.2% change at Actual  
Exchange Rate impacted  
by large non-cash  
impairments of intangible  
assets



Growth & Launch Products continued to demonstrate strong momentum.

43%

Share of Total Revenue

+12.7%

Growth at CER



Core Revenue

¥3,980.0B

Core Operating Profit

¥1,015.0B

Core EPS

¥447

On track towards Management Guidance at CER

Core Revenue

Low-single-digit  
% decline

Core Operating Profit

Low-10s  
% decline

Core EPS

Low-20s  
% decline





This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2023 Q3 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2023 Q3 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/> ) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.